MPR Weekly Dose

Follow MPR Weekly Dose
Share on
Copy link to clipboard

Each week the MPR team brings you the top stories from the world of medicine and pharma in a matter of minutes. With 35 years of publishing drug information behind us, you can rely on MPR to provide accurate and up-to-date news.

MPR Weekly Dose


    • May 15, 2025 LATEST EPISODE
    • weekly NEW EPISODES
    • 11m AVG DURATION
    • 235 EPISODES


    Search for episodes from MPR Weekly Dose with a specific topic:

    Latest episodes from MPR Weekly Dose

    MPR Weekly Dose Podcast #237 — At-Home Cervical CA Screening; FDA Assess Removing Fluoride Products; Chikungunya Vaccination Pause; SC Inj. for Migraine Tx; Gene Therapy for Hunter Syndrome

    Play Episode Listen Later May 15, 2025 15:07


    At-home cervical cancer screening device gains clearance; the FDA indicates it wants to remove pediatric fluoride products from the market; the chikungunya vaccine is put on-pause for some individuals; a subcutaneous autoinjector is approved to treat migraines; and the FDA will review a gene therapy for Hunter syndrome.

    MPR Daily Dose Podcast #236 — Needle-Free Epinephrine for Peds; Oral Semaglutide for Weight Mgmt; Wearable Defibrillator; Hypertension Tx Approved; Stelara Biosimilar

    Play Episode Listen Later May 9, 2025 11:28


    A new epinephrine nasal spray dosage has been approved for pediatrics; FDA agree to review Semaglutide for weight management; A wearable defibrillator is cleared to prevent sudden cardiac arrest; a low dose formulation of chlorthalidone is approved to treat hypertension; and Selarsdi is now interchangeable with Stelara.

    MPR Weekly Dose Podcast #235 — Rinvoq Approval Expanded; Wegovy Telehealth Link-Up; Epidermolysis Bullosa Wound Healing Tx; Imaavy Approved for gMG; Nasal Powder to Treat Migraines

    Play Episode Listen Later May 2, 2025 15:06


    Rinvoq approved for giant cell arteritis; telehealth companies collaborate with Novo Nordisk for Wegovy access; epidermolysis bullosa wound healing treatment approved; Imaavy approved for gMG; New nasal powder approved for migraine treatment.

    MPR Weekly Dose Podcast #234 — Alert for Compounded Finasteride; Cytisinicline Improves Smoking Cessation; GERD Tx Shows Promise; ACIP Makes New Vaccine Recs

    Play Episode Listen Later Apr 25, 2025 15:21


    The FDA issues alert regarding a compounded topical finasteride; plant-based alkaloid shows improvement for smoking cessations; potential new treatment option for GERD; and the CDC's Advisory Committee on Immunization Practices make new recommendations.

    MPR Weekly Dose Podcast #233 — Pfizer ends development of weight loss drug; counterfeit Ozempic seized; daily pill demonstrates HbA1c reductions; mavacamten misses trial endpoint; smart belt to reduce fall injury

    Play Episode Listen Later Apr 18, 2025 12:36


    Pfizer ends danuglipron clinical program for obesity; FDA warns about counterfeit Ozempic; daily pill shows promise in reducing HbA1c; mavacamten misses in nonobstructive HCM trial and the FDA clears smart belt device reduce fall injury.

    MPR Weekly Dose Podcast #232 — Uplizna gains new approval; Vanrafia approved for proteinuria in IgAN; schizophrenia ER Tx now available; Imcivree shows promise in hypothalamic obesity; GLP-1RAs may reduce dementia risk

    Play Episode Listen Later Apr 11, 2025 15:12


    Uplizna gains new indication; Vanrafia approved for proteinuria in IgAN; Erzofri now available for schizophrenia; setmelanotide shows promise in hypothalamic obesity; GLP-1RAs may reduce dementia risk.  

    MPR Weekly Dose Podcast #231 — Treatment for hyperphagia in Prader-Willi Syndrome; Qfitlia Approved; Chlamydia Vaccine and OTC Test; Semaglutide Improves Walking; Imfinzi Approved for MIBC

    Play Episode Listen Later Apr 4, 2025 16:59


    New treatments for Prader-Willi Syndrome and hemophilia; FDA fast tracks a chlamydia vaccine candidate; over-the-counter test cleared for identifying chlamydia, gonorrhea and trichomoniasis; semaglutide improves walking ability in patients with peripheral artery disease; and Imfinzi combo therapy approved for MIBC.    

    MPR Weekly Dose Podcast #230 — New Antibiotic for uUTIs; Treatment Approved for Advanced Neuroendocrine Tumors; New Rosacea Tx Option; Tremfya Gains Crohn Disease Indication; Dept. of HHS Cuts 10,000 Jobs

    Play Episode Listen Later Mar 28, 2025 15:15


    New antibiotic has been approved for uncomplicated UTIs; Cabometyx approved for advanced neuroendocrine tumors; new rosacea treatment option; Tremfya gains Crohn disease indication; Department of HHS cuts 10,000 jobs. 

    MPR Weekly Dose Podcast #229 — Flu Vaccine Recommendations; Patient Dies Following Gene Therapy; Chikungungya Vaccine; Zunveyl Available; REMS Removed for Tryvio

    Play Episode Listen Later Mar 21, 2025 11:37


    Influenza vaccine recommendations made for upcoming season; a patient dies following Elevidys infusion; Chikungunya vaccine now available and recommended for those traveling to areas with an outbreak; novel Alzheimer disease treatment launches; risk evaluation and mitigation strategies removed for hypertension treatment.

    MPR Weekly Dose Podcast #228 — Xolair biosimilar approved; Furoscix indication expanded; Novel implant for rare eye disease; Lorundrostat trial data; Elevated benzene in acne treatments

    Play Episode Listen Later Mar 14, 2025 13:21


    First Xolair biosimilar approved, Wearable furosemide loop diuretic gains expanded indication; Implant approved for macular telangiectasia; Novel treatment shows promise in hypertension; And testing reveals high benzene levels in over-the-counter acne treatments.

    MPR Weekly Dose Podcast #227 — Labeling Changes for Testosterone Products; Food Allergy Treatments Compared; FDA Approves Stroke Tx; COVID-19, Flu Vaccine Effectiveness for Recent Season; Neffy 1mg Approved

    Play Episode Listen Later Mar 6, 2025 15:07


    Labeling changes for testosterone products; food allergy treatments compared; FDA approves stroke Tx; COVID-19, flu vaccine effectiveness for recent season; Neffy 1mg approved

    MPR Weekly Dose Podcast #226 — REMS Removed for Schizophrenia Tx; New Copper Intrauterine Device; Wegovy, Ozempic Supply Update; Lumbar Disc Disease Tx Fast Tracked; Tourette Syndrome Shows Promise

    Play Episode Listen Later Feb 28, 2025 11:37


    REMS requirement removed for schizophrenia treatment; new copper intrauterine device approved; Wegovy, Ozempic no longer in short supply; stem cell therapy for chronic lumbar disc disease fast tracked; ecopipam shows promise for Tourette syndrome.

    MPR Weekly Dose 225 — New Vaccine Approvals; Skin Prep Recalled; Insulin Biosimilar Approved; Twice-yearly lenacapavir to be reviewed

    Play Episode Listen Later Feb 20, 2025 12:48


    New vaccines to protect against meningococcal disease and chikungunya virus; skin prep product recalled due to fungal contamination; rapid-acting insulin biosimilar approved; and twice-yearly lenacapavir gets FDA's priority review for HIV PrEP.

    MPR Weekly Dose Podcast #224 — Strategy for High-Threshold Peanut Allergy; Emblaveo Approved for Complicated Infections; New Formulation of Evrysdi; FDA Fast Tracks Designations Investigational Agents for Alzheimer Disease and Cannabis Use Disorder.

    Play Episode Listen Later Feb 13, 2025 12:31


    Study identifies potential treatment strategy for high-threshold peanut allergy; Emblaveo approved for complicated intra-abdominal infections; new tablet formulation of Evrysdi; FDA fast tracks investigational agents for Alzheimer disease and cannabis use disorder.  

    MPR Weekly Dose 223 — Diabetes Devices Alert Warning; Continuous Apomorphine Device Approved for Parkinson Disease; Symbravo Approved; New Pain Tx; Propranolol May Cut Stroke Risk

    Play Episode Listen Later Feb 7, 2025 15:21


    FDA say there are reports that diabetes patients are missing critical safety data from their smartphone devices; A wearable continuous apomorphine infusion device has been approved for Parkinson disease ‘off' periods; New migraine and pain treatments get the green light; And a study suggest propranolol may cut stroke risk in certain patients.  

    MPR Weekly Dose 222 — Ozempic expanded approval; MS treatment gets Boxed Warning; Monotherapy approval for Spravato; Alzheimer Tx maintenance regimen; Enhertu new Breast CA indication

    Play Episode Listen Later Jan 30, 2025 13:50


    Ozempic gains expanded approval; MS treatment gets Boxed Warning added to label; Monotherapy approval granted for treatment resistant depression Tx Spravato; Leqembi gains  maintenance regimen; Enhertu gains new Breast CA indication.  

    MPR Weekly Dose Podcast #221 — OTC Phenylephrine Removal; Schizophrenia Drug Efficacy Data; FDA Vote on Sotagliflozin; IV Ibuprofen vs Ketorolac; Semaglutide Improves Liver Fibrosis

    Play Episode Listen Later Nov 8, 2024 13:16


    The FDA has issued a proposal to remove a common decongestant in over the counter products; A follow-up study assesses the efficacy of a schizophrenia treatment; The FDA's Endocrinologic and Metabolic Drugs Advisory Committee panel takes vote on the potential of approving a new diabetes treatment; IV ibuprofen adverse reactions examined; And semaglutide found to improve liver fibrosis.  

    Illegal Online Pharmacies: An interview with Libby Baney, senior advisor to the Alliance for Safe Online Pharmacies

    Play Episode Listen Later Nov 4, 2024 25:08


    Libby Baney, Senior Advisor to ASOP Global and a partner at Faegre Drinker Consulting, talks to MPR about the current state of online pharmacies and what is being done to protect patients. 

    MPR Weekly Dose Podcast #219 — Hurricane Helene Impacts IV Supply; At-Home COVID/Flu Test; Fake Online Pharmacies; Depression Tx Fast Tracked; Cologuard Plus Cleared

    Play Episode Listen Later Oct 11, 2024 11:28


    Supplies of a significant number of IV solutions have been impacted by Hurricane Helene; First at-home COVID-19/Flu over-the-counter antigen test gains market authorization; DOJ clamp down on fake online pharmacies; Investigational therapy Fast Tracked for treatment resistant depression; and Cologuard Plus gets cleared for colorectal cancer screening. 

    MPR Weekly Dose Podcast #218 — Novel Weight Management Tx; Complete Response Letter for Tradipitant; Apple's Sleep Apnea Feature Cleared; New Keytruda Indication; Ebglyss for Atopic Dermatitis

    Play Episode Listen Later Sep 20, 2024 13:18


    The FDA clears capsule that creates sensation of fullness in the stomach; Complete Response Letter issued for gastroparesis treatment; Apple's sleep apnea notification feature gets clearance; Keytruda gains malignant pleural mesothelioma indication; Ebglyss approved for atopic dermatitis

    MPR Weekly Dose Podcast #217 — Novel Ulcerative Colitis Tx; Once-Weekly Insulin Efsitora in T1D; Dupilumab for Urticaria; Ultra-Long Acting Biologic in Asthma; Results for Herpes Vaccine

    Play Episode Listen Later Sep 13, 2024 12:21


    New drug approved to treat ulcerative colitis; Once-weekly insulin efsitora investigated in type 1 diabetes; Dupilumab shows efficacy for treating urticaria; A twice-yearly injection shows potential for treating severe asthma; and GSK calls an end to their development of a herpes vaccine.

    MPR Weekly Dose Podcast #216 — Vaccine Guidance for Flu Season; Mpox Vaccine; Updated Novavax Vaccine Authorization; OTC Gel for ED; New Insertion Device for Paragard

    Play Episode Listen Later Sep 6, 2024 12:46


    CDC Advisory Committee issue vaccine guidelines for flu season; Smallpox vaccine gains expanded indication; Updated Novavax COVID-19 vaccine; Over-the-counter gel for erectile dysfunction; New inserter system for placement of contraceptive intrauterine system.

    MPR Weekly Dose Podcast #215 — HIV Drug Discontinuation; Combo for EGFR-Mutated NSCLC; Update on Unapproved Potassium Phosphates in Peds; Otezla Indication Expanded; Tirzepatide Diabetes Risk Reduction Trial

    Play Episode Listen Later Aug 23, 2024 12:38


    Genentech decide to remove Fuzeon from US market; Rybrevant and Lazcluze approved as first-line treatment for certain patients with EGFR-mutated advanced NSCLC; FDA warning regarding unapproved potassium phosphates; Otezla approval expanded to include treatment of pediatric patients; Results from tirzepatide diabetes risk reduction study.

    MPR Weekly Dose Podcast #214 — Livdelzi Approved for PBC; Novel Prurigo Nodularis Tx; FDA Denies MDMA Therapy; Yorvipath Approved; Digital Therapy for MDD

    Play Episode Listen Later Aug 16, 2024 14:19


    New Treatment for Primary Biliary Cholangitis; Nemluvio approved for prurigo nodularis; FDA Denies MDMA for PTSD; New hypoparathyroidism treatment; First digital therapeutic approved for depression.

    MPR Weekly Dose Podcast #213 — Obesity Drug Shortage Update; Updated Contraceptive Recs; Synovial Sarcoma T-Cell Tx; Lymphir Approved; Fabhalta Gains a New Indication

    Play Episode Listen Later Aug 9, 2024 17:44


    The FDA give an updated on the availability of obesity drugs; The CDC has issued an updated guideline on contraceptive use; The first T-cell gene therapy is approved for synovial sarcoma; Lymphir gains approval for relapsed or refractory cutaneous T-cell lymphoma; Fabhalta gains a new indication.

    MPR Weekly Dose Podcast #212 — Compounded Semaglutide Errors; New Alzheimer Disease Tx; Test for Colorectal Cancer; Leqselvi Approved for Alopecia; Palforzia Expanded Approval

    Play Episode Listen Later Aug 2, 2024 14:09


    FDA voice concerns over compounded semaglutide; New treatment approved for mild to moderate dementia of the Alzheimer type; Colorectal cancer screening test gets green light; Leqselvi approved for alopecia; And peanut allergy treatment gains expanded indication.

    MPR Weekly Dose Podcast #211 — Duvyzat Available; Device to Treat Nasal Congestion; Pediatric Tx to Delay Diabetes; Soliris Biosimilar; First Orally-Disintegrating Contraceptive

    Play Episode Listen Later Jul 26, 2024 12:16


    Duchenne muscular dystrophy treatment now available; Noise therapy wearable for nasal congestion; Treatment for delaying diabetes gets Fast Tracked; Soliris biosimilar approved; And the first orally-disintegrating contraceptive.

    MPR Weekly Dose Podcast #210 — Clonazepam ODT Recall; Parkinson Disease Tx Gets Fast Tracked; Pancreatic CA Vaccine; Voquenzna New Approval; Endari Generic

    Play Episode Listen Later Jul 19, 2024 14:11


    Seizure medication recalled due to wrong strength on carton; Gene therapy gains Fast Track status for Parkinson disease; Dendritic cell vaccine being developed for pancreatic cancer; Generic version of sickle cell disease treatment Endari is made available

    MPR Weekly Dose Podcast #209 — Atopic Dermatitis Topical; Wet AMD Implant Available Again; Neurostimulation Device for RA; FDA Denies Weekly Insulin; Smarthphone Therapy for Fibromyalgia

    Play Episode Listen Later Jul 12, 2024 12:56


    New steroid-free topical for atopic dermatitis; A refillable ocular implant for the treatment of  neovascular (wet) age-related macular degeneration returns following recall; A neuroimmune modulation device shows clinical benefit in adults with rheumatoid arthritis; FDA denies Novo Nordisk's once-weekly insulin icodec; And a smarthphone therapy shows benefit for patients with fibromyalgia.

    MPR Weekly Dose Podcast #208 — Ohtuvayre Approved; Generic Victoza; DMD Gene Therapy Expanded; Treatment for Pediatric Narcolepsy; OTC Video Game for ADHD

    Play Episode Listen Later Jun 28, 2024 12:21


    New maintenance treatment approved for COPD; Authorized generic version of Victoza launches; Duchenne muscular dystrophy treatment indication expanded; Narcolepsy treatment expanded for certain pediatric patients; FDA clears digital therapeutic for ADHD.  

    MPR Weekly Dose Podcast #207 — Skyrizi for UC; 21-Valent Pneumococcal Vaccine; Indictment May Affect ADHD Meds; Next-Gen COVID-19 Vaccine; Farxiga Approval Expanded

    Play Episode Listen Later Jun 21, 2024 13:30


    Skyrizi has been approved for ulcerative colitis; New pneumococcal vaccine approved; An indictment may impact as much as 50,000 patients who need ADHD meds; Results announced for Moderna's next-gen COVID-19 vaccine; Farxiga approval expanded.

    MPR Weekly Dose 206 — OTC Glucose Monitors; RSV Vaccine Approval Expanded; Juvenile Idiopathic Arthritis Tx; Emflaza Generic; New Primary Biliary Cholangitis Tx

    Play Episode Listen Later Jun 14, 2024 11:34


    Two glucose monitoring systems have been cleared for over-the-counter sale; Arexvy gains approval for adults aged 50 to 59 years; Kevzara approved for active polyarticular juvenile idiopathic arthritis; Generic Duchenne muscular dystrophy drug is made available; and Iqirvo gets accelerated approval for primary biliary cholangitis.

    MPR Weekly Dose Podcast #205 — Entresto Generics; mRNA-Based RSV Vaccine; Doxycycline PEP for STI Prevention; FDA Vote on MDMA Therapy; Rinvoq Indication Expanded

    Play Episode Listen Later Jun 7, 2024 11:56


    First generics of heart failure drug gain approval; mRNA vaccine approved for RSV; CDC make drug recommendation for STI prevention; Advisory Committee vote on MDMA for PTSD; Rinvoq approval expanded

    MPR Weekly Dose 204 — Novel ADHD Extended-Release Tx; Soliris Biosimilar Approved; Depression, Insomnia Tx; FDA Vote on Colorectal CA Test; Mistrust in the FDA

    Play Episode Listen Later May 31, 2024 11:49


    Extended-release ADHD treatment gains approval; An interchangeable biosimilar to Soliris is approved; Investigational treatment shows promise for improving depression and insomnia; The FDA vote on a blood-based colorectal cancer diagnostic; Survey reveals public attitudes towards the FDA.

    MPR Weekly Dose Podcast 203 — Urinary Incontinence Device; Autoinjector Warning for MS Tx; COVID-19 Preexposure Prophylaxis; Elyea Biosimilars; Lung Cancer Treatment Approved

    Play Episode Listen Later May 24, 2024 14:19


    Self-administered device cleared to treat stress urinary incontinence in women; Autoinjector warning for relapsing MS treatment; COVID-19 preexposure prophylaxis investigational treatment looks promising; Biosimilars for Eylea approved; Imdelltra approved for extensive stage small cell lung cancer with disease progression.  

    MPR Weekly Dose 202 — Unreliable COVID-19 Tests; Insulin Pump App Update; Noninvasive Colorectal CA Test; Self-Collection HPV Screening Option; Drug Threats to the US

    Play Episode Listen Later May 17, 2024 11:09


    Reliability of COVID-19 tests unreliable; Insulin pump app updated following battery issue; Noninvasive colorectal cancer test gets FDA approval; Self-collection HPV screening option; National Drug Threat Assessment highlights illicit drugs currently endangering the US. 

    Drug Shortage Crisis: An interview with Dr. Michael Ganio

    Play Episode Listen Later May 10, 2024 13:54


    Dr. Michael Ganio, ASHP's Director of Pharmacy Practice and Quality, joins me to discuss the current drug shortage crisis, which has reached new levels.

    Psilocybin for Depression: An interview with Dr. Charles Raison

    Play Episode Listen Later Apr 30, 2024 28:53


    Dr Charles Raison, the Director of Clinical Research at the Usona Institute and Professor in the Department of Psychiatry at the University of Wisconsin–Madison, joins me to discuss the potential of psilocybin as a therapy for major depressive disorder.

    MPR Weekly Dose 199 — Fasenra Expanded Approval; HIV Tx Approval Expanded; ALS Drug Discontinued; CRL for Apomorphine Device; At-Home Mpox Test

    Play Episode Listen Later Apr 12, 2024 11:25


    Asthma treatment gains approval for severe cases in pediatrics; Dovato gains expanded indication; Decision taken to remove ALS drug from market; Complete Response Letter issued for apomorphine device; At-home Mpox test kit made available.

    MPR Weekly Dose 198 — Prescription App for MDD; Traumatic Brain Injury Blood Test; New Bloodstream Infection Antibiotic; Mpox Vaccine Availability; Left Ventricular Ejection Fraction Detection

    Play Episode Listen Later Apr 5, 2024 11:40


    First prescription smartphone app approved for major depressive disorder; Novel blood test to detect TBI; Zevtera approved for bloodstream infections; Mpox vaccine is now commercially available; Algorithm cleared for LVEF dectection.  

    MPR Weekly Dose 197 — Pemgarda Emergency Use; Expansion of Nexletol, Nexlizet; DMD Drug Approval; First Molecular Malaria Blood Test; OTC Topical Analgesic Warning

    Play Episode Listen Later Mar 29, 2024 13:32


    Preexposure prophylaxis approved for COVID-19; Nexletol and Nexlizet gain expanded approval; Novel Duchenne muscular dystrophy treatment; First blood test to screen for malaria in donors; Warning letter for OTC topical analgesic products.  

    MPR Weekly Dose 196 — Chronic Rhinosinusitis Nasal Spray; Novel hypertension Tx; Stem-Cell Treatment Approved for Rare Disease; Accelerated approval for NASH Tx; Automated Insulin Delivery System

    Play Episode Listen Later Mar 22, 2024 14:10


    Nasal spray approved for chronic rhinosinusitis; Endothelin receptor antagonist gains approval to lower blood pressure in hypertension; One-time stem cell treatment approved for metachromatic leukodystrophy; NASH treatment gains accelerated approval; New automated insulin delivery system for type 1 diabetes.  

    MPR Weekly Dose 195 — Weight Loss Tx Gains Cardiovascular Indication; Paxlovid Update; Psilocybin Granted Breakthrough Therapy; Decision Delay for Alzheimer Tx; Relyvrio Trial Results

    Play Episode Listen Later Mar 15, 2024 13:11


    Weight loss treatment has approval expanded; Paxlovid with Emergency Use Authorized label must be disposed of; psychedelic gets Breakthrough therapy designation; Advisory Committee announce meeting to discuss Alzheimer treatment; ALS treatment trial results

    MPR Weekly Dose 194 — OTC Birth Control Pill; First OTC Continuous Glucose Monitor; Influenza Vaccine for 2024/2025 Season; Breakthrough Therapy for LSD; Biosimilars to Prolia and Xgeva

    Play Episode Listen Later Mar 8, 2024 13:36


    Over-the-counter birth control pill to be available in the coming weeks; first over-the-counter continuous glucose monitor to be available starting this summer; the 2024-2025 US influenza season vaccine will be trivalent; LSD granted Breakthrough Therapy for treatment of generalized anxiety disorder; interchangeable biosimilars to Prolia and Xgeva approved. 

    MPR Weekly Dose 193 — Pepaxto Approval Withdrawn; Abrysvo Efficacy; Ixchiq Vaccine Recommendations; Novel Schizophrenia Tx Decision; UTI Tx Approval; Eye Ointment Recalled

    Play Episode Listen Later Mar 1, 2024 17:01


    FDA withdraw multiple myeloma treatment after a confirmatory trial showed an increased risk of death; latest efficacy results for lower respiratory tract disease vaccine; CDC Chikungunya virus vaccine recommendations; Complete Response Letter issued to investigative schizophrenia treatment; new treatment for complicated UTIs including pyelonephritis; over-the-counter eye ointments recalled.  

    MPR Weekly Dose 192 — Xolair Approved for Multiple Food Allergies; Amtagvi Gets Approval; Vit D Supplement Recalled; Cannabidiol for Pericarditis; Smartwatch Warning

    Play Episode Listen Later Feb 23, 2024 13:36


    First treatment approved to reduce allergic reactions in those with multiple food allergies; T-cell therapy given accelerated approval to treat unresectable or metastatic melanoma; Vit D supplement recalled due to superpotency; cannabidiol may help resolve the symptoms of pericarditis; FDA warn against certain wearables that claim to measure blood glucose.

    MPR Weekly Dose 191 — First FDA-Approved Tx for Frostbite; New Eosinophilic Esophagitis Tx; Psychoactive Accepted for Review for PTSD; Novel Tx for Prurigo Nodularis; OTC Oximeter

    Play Episode Listen Later Feb 16, 2024 14:07


    FDA approves first treatment for severe frostbite; Eohilia gains approval to treat eosinophilic esophagitis; MDMA accepted for Priority Review for PTSD; novel subcutaneous to be reviewed for prurigo nodularis, atopic dermatitis; OTC pulse oximeter device is cleared.

    MPR Weekly Dose 190 — Nonopioid Pain Med; Dental Pain Management; Arexvy Review; Magrolimab Development Ended; Athlete's Foot Spray Recalled

    Play Episode Listen Later Feb 9, 2024 14:37


    Combination intravenous formulation of acetaminophen and ibuprofen approved; recommendations from the ADA for dealing with acute dental pain; RSV vaccine under review for younger adult age group; Gilead call halt on investigational leukemia treatment hagrolimab; athlete foot spray recalled.

    MPR Weekly Dose 189 — Alzheimer Drug Discontinued; New Acne Vulgaris Guidelines; Paxlovid Update; ADHD Drug Recall; Safety Alert for Copycat Eye Drops

    Play Episode Listen Later Feb 2, 2024 12:31


    Biogen discontinue Alzheimer treatment; The American Academy of Dermatology issue new acne vulgaris management guidelines; Update for ongoing availability of Paxlovid; Narcolepsy/ADHD treatment recalled for containing wrong drug; FDA warn against copycat eye drop products

    MPR Weekly Dose 188 — Labeling Changes for T-Cell Immunotherapies; Novel Opioid Therapy; Boxed Warning for Prolia; At-Home Insemination Kit; Novel Rescue Inhaler

    Play Episode Listen Later Jan 26, 2024 12:57


    T-cell malignancies prompt label changes for certain T-cell immunotherapies; Novel opioid provides in-built protection against overdose; Hypocalcemia risk with Prolia; At-Home semen insemination kit cleared; New asthma rescued medicine approved

    MPR Weekly Dose 187 — Gene Therapy for TDT; HyQvia Approved for CIDP; Handheld Skin Assessing Device; Vertebral Strength Device for Low-Bone Mass; Narcan Shelf-Life Extended

    Play Episode Listen Later Jan 19, 2024 13:32


    Gene therapy approved for beta thalassemia; treatment for preventing of chronic inflammatory demyelinating polyneuropathy relapse; device to aid dermatologist referrals; vertebral strength device for low-bone mass; Narcan shelf-life extension

    Claim MPR Weekly Dose

    In order to claim this podcast we'll send an email to with a verification link. Simply click the link and you will be able to edit tags, request a refresh, and other features to take control of your podcast page!

    Claim Cancel